Citicoline showed no clear difference in disability or dependence in daily activities Patients with moderate… compared with placebo or standard treatment (low certainty).
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe cognitive delay at 18… compared with expectant management (low certainty).
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe motor delay at 18 to 24… compared with expectant management (low certainty).
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe language delay at 18 to… compared with expectant management (low certainty).
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations compared with placebo (moderate certainty).
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).
Clinical examination with risk-based recall showed no clear difference in dental caries: prevalence of moderate to extensive caries (ICDAS 3-6) compared with clinical examination with 6-month recall (moderate certainty).
Clinical examination with risk-based recall showed no clear difference in dental caries: prevalence of moderate to extensive caries (ICDAS 3-6) compared with clinical examination with 24-month recall (moderate certainty).